
94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
ORIGINAL RESEARCH article
Front. Pharmacol. , 31 January 2020
Sec. Pharmacology of Anti-Cancer Drugs
Volume 10 - 2019 | https://doi.org/10.3389/fphar.2019.01700
A retraction of this article was approved in:
Retraction: Long noncoding RNA FOXD2-AS1 promotes the malignancy of cervical cancer by sponging microRNA-760 and upregulating hepatoma-derived growth factor
Citation: Dou X, Zhou Q, Wen M, Xu J, Zhu Y, Zhang S and Xu X (2020) Long Noncoding RNA FOXD2-AS1 Promotes the Malignancy of Cervical Cancer by Sponging MicroRNA-760 and Upregulating Hepatoma-Derived Growth Factor. Front. Pharmacol. 10:1700. doi: 10.3389/fphar.2019.01700
Received: 29 September 2019; Accepted: 31 December 2019;
Published: 31 January 2020; Retracted: 05 January 2023.
Edited by:
Olivier Feron, Université Catholique de Louvain, BelgiumDisclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Research integrity at Frontiers
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.